福泰製藥(VRTX)：高級副總裁提高了指導預期至106.5億至108.5億美元，反映出9%的增長

市場資訊

2024-09-19

來源：Gangtise投研

福泰製藥(VRTX) 在2024年的Jefferies工業會議上，高級副總裁Susie Lisa討論了公司的當前狀況和未來方向。她強調了公司在囊性纖維化（CF）治療領域的強勁商業執行力，並提高了指導預期至106.5億至108.5億美元，反映出9%的增長。Lisa還提到了公司在疼痛治療領域的多元化商業戰略，特別是在慢性疼痛和外周神經性疼痛方面的進展，以及公司在糖尿病細胞療法方面的研究。此外，她提到了公司對Alpine Immune Sciences的收購，這將加強公司在自身免疫疾病領域的地位。Lisa對公司的長期增長潛力持樂觀態度，並強調了公司在生產力提升和資源分配方面的戰略重點。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：張倩

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2468593967"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468593967\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2468593967?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-09-19 08:57","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2468593967","market":"other","top_or_hot":-1,"title":"福泰製藥(VRTX)：高級副總裁提高了指導預期至106.5億至108.5億美元，反映出9%的增長","media":"市場資訊","content":"<html><body><div>\n<p><strong><span>來源：Gangtise投研</span></strong></p>\n<p><strong><span><a href=\"https://laohu8.com/S/VRTX\">福泰製藥</a>(VRTX) </span></strong><span>在2024年的Jefferies工業會議上，高級副總裁Susie Lisa討論了公司的當前狀況和未來方向。她強調了公司在囊性纖維化（CF）治療領域的強勁商業執行力，</span><strong><span>並提高了指導預期至106.5億至108.5億美元，反映出9%的增長。</span></strong><span>Lisa還提到了公司在疼痛治療領域的多元化商業戰略，</span><strong><span>特別是在慢性疼痛和外周神經性疼痛方面的進展，以及公司在糖尿病細胞療法方面的研究。</span></strong><span>此外，她提到了</span><strong><span>公司對Alpine Immune Sciences的收購，這將加強公司在自身免疫疾病領域的地位。</span></strong><span>Lisa對公司的長期增長潛力持樂觀態度，並強調了公司在生產力提升和資源分配方面的戰略重點。</span></p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張倩 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>福泰製藥(VRTX)：高級副總裁提高了指導預期至106.5億至108.5億美元，反映出9%的增長</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n福泰製藥(VRTX)：高級副總裁提高了指導預期至106.5億至108.5億美元，反映出9%的增長\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">市場資訊</strong><span class=\"h-time small\">2024-09-19 08:57</span>\n</p>\n</header>\n<article>\n<div>\n<p><strong><span>來源：Gangtise投研</span></strong></p>\n<p><strong><span><a href=\"https://laohu8.com/S/VRTX\">福泰製藥</a>(VRTX) </span></strong><span>在2024年的Jefferies工業會議上，高級副總裁Susie Lisa討論了公司的當前狀況和未來方向。她強調了公司在囊性纖維化（CF）治療領域的強勁商業執行力，</span><strong><span>並提高了指導預期至106.5億至108.5億美元，反映出9%的增長。</span></strong><span>Lisa還提到了公司在疼痛治療領域的多元化商業戰略，</span><strong><span>特別是在慢性疼痛和外周神經性疼痛方面的進展，以及公司在糖尿病細胞療法方面的研究。</span></strong><span>此外，她提到了</span><strong><span>公司對Alpine Immune Sciences的收購，這將加強公司在自身免疫疾病領域的地位。</span></strong><span>Lisa對公司的長期增長潛力持樂觀態度，並強調了公司在生產力提升和資源分配方面的戰略重點。</span></p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張倩 </p>\n</div>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/2024-09-19/doc-incprwmu7159855.shtml\">市場資訊</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417517546.SGD","symbol_name":"Allianz US Equity Cl AT Acc SGD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/2024-09-19/doc-incprwmu7159855.shtml","article_id":"2468593967","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468593967","pubTimestamp":1726707420,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"福泰製藥在2024年的Jefferies工業會議上，高級副總裁Susie Lisa討論了公司的當前狀況和未來方向。她強調了公司在囊性纖維化治療領域的強勁商業執行力，並提高了指導預期至106.5億至108.5億美元，反映出9%的增長。Lisa還提到了公司在疼痛治療領域的多元化商業戰略，特別是在慢性疼痛和外周神經性疼痛方面的進展，以及公司在糖尿病細胞療法方面的研究。Lisa對公司的長期增長潛力持樂觀態度，並強調了公司在生產力提升和資源分配方面的戰略重點。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","VRTX":"福泰制药","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"translate_title":"Fortex Pharmaceuticals (VRTX): SVP Raises Guidance Estimate to $10.65 Billion to $10.85 Billion, Reflecting 9% Growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"來源：Gangtise投研\n福泰製藥(VRTX) 在2024年的Jefferies工業會議上，高級副總裁Susie Lisa討論了公司的當前狀況和未來方向。她強調了公司在囊性纖維化（CF）治療領域的強勁商業執行力，並提高了指導預期至106.5億至108.5億美元，反映出9%的增長。Lisa還提到了公司在疼痛治療領域的多元化商業戰略，特別是在慢性疼痛和外周神經性疼痛方面的進展，以及公司在糖尿病細胞療法方面的研究。此外，她提到了公司對Alpine Immune Sciences的收購，這將加強公司在自身免疫疾病領域的地位。Lisa對公司的長期增長潛力持樂觀態度，並強調了公司在生產力提升和資源分配方面的戰略重點。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張倩","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}